Withdrawals due to adverse events · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with acute pouchitis
It is very uncertain whether metronidazole changes adverse events compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical remission · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical remission compared with budesonide enema (very low certainty).
1 finding from 1 review
Clinical improvement · Patients with acute pouchitis
It is very uncertain whether metronidazole changes clinical improvement compared with budesonide enema (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
No episodes of acute pouchitis · Patients with acute pouchitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease
Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).
2 findings from 1 review
Withdrawals due to adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Serious adverse events · maintenance of remission in Crohn's disease
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
1 finding from 1 review
Maintenance of remission · maintenance of remission in Crohn's disease
Azathioprine may leads to higher maintenance of remission compared with budesonide (low certainty).
1 finding from 1 review